MedTrace Logo

Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects

NCT00789126 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2009-02-19

No results posted yet for this study

Summary

Study to evaluate the safety and tolerability of single ascending doses and multiple ascending doses of VX-509 administered to healthy male and female subjects

Conditions

  • Healthy

Interventions

DRUG

VX-509

Sponsors & Collaborators

Principal Investigators

  • George Spencer-Green, MD, MS · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00789126 on ClinicalTrials.gov